Another mechanism of KRAS G12C treatment resistance is due to intratumor heterogeneity, with the KRAS mutation co-existing with various mutations in different tumor clones; combinations of driver mutations in LUAD is generally associated with increased resistance to TKI, and targeted therapies should be considered during treatment [28,29]. Here, KRAS is linked to neoplasm.